amycretin novo nordisk

Novo Nordisk, amycretin

Novo Nordisk next-gen shot shows 22% weight loss in early results

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Hosted on MSN · 3d

Novo Nordisk shares pop on early-stage weight loss drug trial results

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

YAHOO!Finance · 3d

Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,

Pharmabiz12h

Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity: Bagsværd, Denmark Monday, January 27, 2025, 13:00 ...

2don MSN

The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week

Here are some of the major companies whose stocks moved on the week’s news.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk, amycretin

Trending now